Holen Sie sich die Stockscreener-App
1.845
0.27%
0.005
Handel nachbörslich:
1.88
0.035
+1.90%
Schlusskurs vom Vortag:
$1.84
Offen:
$1.81
24-Stunden-Volumen:
1.17M
Relative Volume:
0.80
Marktkapitalisierung:
$131.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.50M
KGV:
-0.7688
EPS:
-2.4
Netto-Cashflow:
$-114.31M
1W Leistung:
+29.02%
1M Leistung:
+5.43%
6M Leistung:
-56.18%
1J Leistung:
-82.95%
1-Tages-Spanne:
$1.7801
$1.915
1-Wochen-Bereich:
$1.31
$2.34
52-Wochen-Spanne:
$1.31
$10.48
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Vergleichen Sie NKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.845 | 131.63M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.36B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.95B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.13B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-28 | Eingeleitet | Needham | Buy |
| 2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
| 2022-03-11 | Eingeleitet | Raymond James | Outperform |
| 2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-06 | Eingeleitet | William Blair | Outperform |
| 2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2020-08-04 | Eingeleitet | Cowen | Outperform |
| 2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-04 | Eingeleitet | Mizuho | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Earnings on Thursday - Defense World
NKTX stock touches 52-week low at $1.69 amid market challenges - Investing.com
Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely? - Simply Wall St
Nkarta to Participate in March Investor Conferences - The Manila Times
NKTX stock touches 52-week low at $1.96 amid market challenges - Investing.com
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus
What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register
Nkarta's chief medical officer sells $19,003 in stock - MSN
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nkarta Inc-Aktie (NKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
| Hager Alicia J. | Chief Legal Officer |
Jul 16 '24 |
Sale |
8.00 |
3,396 |
27,168 |
103,819 |
| Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
| Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
| Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
| Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):